Stocks that are currently undervalued and recommended for purchase by financial experts, potentially before they become widely owned by others!
In the ever-evolving world of finance, three prominent companies – Federated Hermes, United Therapeutics, and PayPal – have caught the attention of investors. Here's a closer look at their current market positions and expert insights.
### Federated Hermes (NYSE: FHI)
As of July 8, 2025, Federated Hermes is trading around $45.51 per share, not far from its 52-week high of $46.24. The asset management giant, with over $782 billion in assets under management, has displayed strong upward momentum, with a 35.1% increase over the past year.
Recent earnings reports revealed a beat on EPS estimates, with $1.10 reported against an expectation of $0.91, and robust Asset Under Management (AUM) growth. The short-term technical outlook is positive, predicting a potential 16.98% rise over the next three months, with a price range between $49.26 and $53.46.
Analysts have a consensus "Hold" rating, but with an average price target of $42.33, suggesting a slight downside (-7.05%) over the next year. Some analysts, however, see higher targets up to $46. Financial expert Ulrich Ebensperger, while not directly cited, seems to have a bullish outlook on Federated Hermes before the end of 2024.
Federated Hermes is known for its focus on sustainable investments and ESG criteria, making it a popular choice among socially conscious investors. The company also offers a dividend yield of around four percent and a P/E ratio of nine for 2025.
### United Therapeutics and PayPal
United Therapeutics, a US biotech company specialising in rare diseases and life-saving therapies, and PayPal, the digital payments giant, did not have specific updated prices, performance trends, or expert recommendations from Ulrich Ebensperger as of mid-2025.
However, it's worth noting that Deutsche Bank sees around 13 percent upside with a price target of 94 USD for PayPal (PYPL).
### United Therapeutics (UTHR)
United Therapeutics is projected to experience an annual market growth of 5.5 percent. Despite a strong track record, the company's P/E ratio stands at 13.2, suggesting it might be considered undervalued.
### In Closing
While Federated Hermes is currently trading near a 52-week high with strong earnings performance and positive short-term price momentum, indicating good potential for growth before the end of 2024, analysts are mixed with a "Hold" consensus but a range of price targets from $40 to $46.
No current detailed data or expert recommendations were found for United Therapeutics and PayPal regarding their prices or performance trends from Ulrich Ebensperger. However, an expert suggests buying three stocks before the end of 2024. Further research and expert analysis can provide more insights into the current market positions and future prospects of these companies.
- An investor considering personal-finance decisions may find it interesting to note that Federated Hermes, currently trading near its 52-week high, offers a dividend yield of around four percent and a P/E ratio of nine for 2025, making it a potential investment choice in the realm of sustainable investments.
- In the realm of investing, United Therapeutics, a biotech company specializing in rare diseases and life-saving therapies, might be considered undervalued, given its strong track record and a P/E ratio of 13.2, although specific expert recommendations for its prices or performance trends were not found as of mid-2025.
